YOLFTbeta
Carvolix

Carvolix

CVX · PA · Healthcare / Medical Devices

4.85EUR-0.09 (-1.82%)

Price History

Full chart

Market Stats

Previous Close4.94
Open5.10
Day Range4.85 – 5.10
52-Week Range1.32 – 7.56
Volume12.56K
Market Cap359.71M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.64
Dividend Yield0.00%
Beta1.09
50-Day Avg5.98
200-Day Avg3.96

About

Carvolix SA, a medical technology company, develops and markets minimally invasive, minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company also offers TAVIPILOT Software, a robotic platform for transcatheter aortic valve implantation; TAVIPILOT Robot, mitral valve repair and replacement solutions; MITRAPILOT, a biomimetic transcatheter mitral valve; and Artedrone, an implantable artificial urinary sphincter. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 2026. Carvolix SA was founded in 2011 and is headquartered in Aix-en-Provence, France.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Sebastien Ladet Ph.D.
  • Employees59
  • Headquarters900 rue Andre Ampere, Aix-en-Provence, France, 13290, France
  • Websitehttps://www.carvolix.eu

Leadership

  • Mr. Sebastien Ladet Ph.D.Chief Executive Officer
  • Mr. Christophe de VregilleChief Financial Officer
  • Ms. Celine BuardHead of marketing & EU Commercialization
  • Melanie CantalHuman Resources Manager
  • Mr. Nicolas Barry Delongchamps M.D.Chief Medical Officer & Member of Scientific Advisory Board
  • Prof. Francois Laborde M.D., Ph.D.Chief Surgical Officer
  • Mr. Olivier PierronDeputy Chief Executive Officer · b. 1969
  • Mr. Benjamin Renault Ph.D.Chief Development Officer
  • Dr. Howard C. Herrmann M.D.Chief Medical Officer
  • Pierre Berthet-Rayne Ph.D.Chief Technology Officer Robotics

Financials

Income Statement

Currency: EUR2016-12-312017-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.00K43.00K1.43M824.00K1.45M1.34M1.22M4.12M-
Growth (%)-+1333.33%+3223.26%-42.34%+76.09%-7.72%-8.59%+236.44%-
Cost of Revenue3.80M10.94M2.26M3.26M2.74M2.44M2.42M13.39M2.19M
Gross Profit-3.79M-10.89M-831.00K-2.44M-1.29M-1.10M-1.20M-9.27M-2.19M
Gross Margin-126500.00%-25337.21%-58.15%-295.63%-88.90%-82.45%-98.04%-225.16%-
Operating Expense3.29M-600.00K14.45M10.56M11.94M10.78M11.87M6.42M15.81M
Operating Income-7.09M-10.29M-15.28M-12.99M-13.23M-11.88M-13.07M-15.69M-18.00M
Operating Margin-236300.00%-23941.86%-1069.56%-1576.70%-911.99%-887.45%-1067.48%-380.99%-
EBITDA-6.94M-9.97M-12.55M-10.47M-10.89M-13.21M-13.34M-13.44M-15.81M
EBITDA Margin-231233.33%-23179.07%-878.38%-1271.12%-750.38%-986.86%-1090.11%-326.44%-
Net Income-5.84M-8.75M-16.59M-14.32M-14.82M-15.23M-15.65M-14.74M-24.97M
Net Income Margin-194566.67%-20353.49%-1160.88%-1737.74%-1021.36%-1137.19%-1278.84%-357.92%-
R&D---9.00K23.00K52.00K72.00K94.00K-
R&D as % of Total Revenue---1.09%1.59%3.88%5.88%2.28%-
Interest Expense36.00K166.00K1.88M2.17M3.06M1.08M393.00K242.00K-
Interest Expense % of Total Revenue1200.00%386.05%131.84%262.74%210.54%80.66%32.11%5.88%-

Balance Sheet

Currency: EUR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets61.72M67.39M68.84M65.25M64.83M70.03M60.02M56.62M60.86M47.83M
Total Liabilities2.85M6.00M21.79M34.29M29.54M26.50M26.19M25.15M30.59M42.28M
Total Equity58.87M61.39M47.06M30.96M35.29M43.53M33.83M31.47M30.27M5.55M
Cash1.63M4.88M3.34M2.13M5.65M11.41M2.58M1.66M1.23M1.75M
Total Debt159.00K2.85M11.55M24.18M20.78M19.75M17.73M17.13M16.33M24.04M
Net Debt-1.47M-2.02M8.21M22.06M15.13M8.34M15.15M15.48M15.10M22.29M

Cash Flow

Currency: EUR2016-12-312017-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--10.84M-11.41M-8.94M-12.36M-11.08M-12.05M-11.32M-11.61M
Investing Cash Flow--270.00K-185.00K-304.00K-160.00K-146.00K-184.00K-480.00K5.25M
Financing Cash Flow-14.36M10.39M12.76M18.28M2.40M11.32M11.37M6.88M
Capital Expenditure0263.00K196.00K304.00K334.00K146.00K184.00K147.00K116.00K
Free Cash Flow--11.11M-11.61M-9.24M-12.70M-11.23M-12.24M-11.47M-11.72M
FCF to OCF-102.43%101.72%103.40%102.70%101.32%101.53%101.30%101.00%

Key Statistics & Ratios

Market Cap359.71M
Enterprise Value379.63M
Trailing P/E0.00
Forward P/E0.00
Price / Sales226.23
Price / Book17.16
EPS-0.64
Book Value0.146
Revenue (TTM)1.59M
Gross Profit (TTM)-2.95M
EBITDA-19.43M
Profit Margin0.00%
Operating Margin-1140.02%
Return on Equity-138.61%
Return on Assets-19.57%
Shares Outstanding62.23M
Shares Float6.52M
Beta1.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%